Skip to main content

Table 2 Baseline characteristics of healthy subjects (human study, multiple-dose phase)

From: Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects

Parameter LCI699 0.5 mg LCI699 1 mg LCI699 3 mg Eplerenone Placebo
n = 12 n = 12 n = 12 n = 10 n = 11
Age, years 33.0 ± 6.0 32.1 ± 7.2 34.2 ± 8.1 32.5 ± 5.2 35.8 ± 7.8
Body weight, kg 80.5 ± 6.1 76.1 ± 6.2 76.8 ± 6.9 79.2 ± 6.0 82.8 ± 8.6
Supine heart rate, bpm 57 ± 5 63 ± 10 61 ± 5 62 ± 9 64 ± 8
Supine blood pressure, mmHg 128/75 ± 8/7 124/73 ± 11/8 123/75 ± 8/4 124/73 ± 9/6 124/74 ± 9/6
Plasma aldosterone, pg/mL 204.8 ± 78.7 186.4 ± 74.5 236.1 ± 85.6 244.9 ± 80.3 224.2 ± 83.5
Plasma cortisol, ng/mL 120.5 ± 35.4 113.5 ± 28.2 112.9 ± 34.7 121.6 ± 46.1 103.4 ± 46.7
Plasma ACTH, pg/mL 21.9 ± 6.9 26.0 ± 9.6 30.7 ± 16.6 26.8 ± 14.1 22.1 ± 14.6
Plasma renin activity, ng/mL/h 1.24 ± 0.59 1.03 ± 0.65 1.00 ± 0.32 1.83 ± 1.36 1.30 ± 1.04
Plasma sodium, mmol/L 140.8 ± 1.4 140.9 ± 1.2 140.8 ± 1.4 141.2 ± 1.3 140.9 ± 2.1
Plasma potassium, mmol/L 4.5 ± 0.3 4.3 ± 0.2 4.5 ± 0.1 4.3 ± 0.3 4.3 ± 0.3
Serum creatinine, μmol/L 94.5 ± 6.5 93.1 ± 10.0 91.5 ± 6.3 90.6 ± 6.9 92.1 ± 4.4
Blood glucose, mmol/L 4.9 ± 0.5 4.9 ± 0.3 5.2 ± 0.5 5.2 ± 0.5 4.9 ± 0.7
  1. Values are mean ± SD unless otherwise stated.